It has been reported that daily subcutaneous administration of VIPhyb, an antagonist of both VIPR1 and VIPR2, induces anti-tumor effects against CT26 cells implanted to severe combined immunodeficient (SCID) mice and enhances the pharmacological effects of an anti-PD-1 antibody [7]. Here, VIPR1 is linked to neoplasm.